• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma.

作者信息

Hearn Andrew P, Kavanagh Joanne, d'Ancona Grainne, Roxas Cris, Green Linda, Thomson Louise, Fernandes Marianna, Kent Brian D, Dhariwal Jaideep, Nanzer Alexanda M, Jackson David J

机构信息

Guy's Severe Asthma Centre, Guy's Hospital, Guy's & St Thomas' NHS Trust, London, United Kingdom; School of Immunology & Microbial Sciences, King's College London, United Kingdom.

Guy's Severe Asthma Centre, Guy's Hospital, Guy's & St Thomas' NHS Trust, London, United Kingdom.

出版信息

J Allergy Clin Immunol Pract. 2021 May;9(5):2093-2096.e1. doi: 10.1016/j.jaip.2021.01.008. Epub 2021 Jan 21.

DOI:10.1016/j.jaip.2021.01.008
PMID:33486140
Abstract
摘要

相似文献

1
The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma.呼出一氧化氮（FeNO）与美泊利单抗和贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘疗效之间的关系。
J Allergy Clin Immunol Pract. 2021 May;9(5):2093-2096.e1. doi: 10.1016/j.jaip.2021.01.008. Epub 2021 Jan 21.
2
[A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].[一例严重哮喘因对贝那利珠单抗出现迟发性无反应而改用美泊利珠单抗的病例]
Arerugi. 2020;69(8):678-682. doi: 10.15036/arerugi.69.678.
3
Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.严重的未控制的嗜酸性粒细胞性哮喘，在对美泊利珠单抗治疗无效后对贝那利珠单抗有反应。
Ann Allergy Asthma Immunol. 2019 Apr;122(4):431-433. doi: 10.1016/j.anai.2018.12.014. Epub 2018 Dec 19.
4
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.贝那鲁肽治疗重症嗜酸性粒细胞性哮喘患者的疗效：一项回顾性真实世界研究。
BMC Pulm Med. 2020 Aug 3;20(1):207. doi: 10.1186/s12890-020-01248-x.
5
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma.在重度嗜酸性粒细胞性哮喘中，美泊利单抗治疗反应欠佳后使用贝那利珠单抗。
Allergy. 2021 Jun;76(6):1890-1893. doi: 10.1111/all.14693. Epub 2020 Dec 23.
6
Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.针对白细胞介素-5 信号通路的抗体作为严重嗜酸性粒细胞性哮喘患者的附加治疗药物：皮下给予美泊利珠单抗和贝那利珠单抗的作用机制、疗效和安全性的综述。
Expert Rev Respir Med. 2020 Apr;14(4):353-365. doi: 10.1080/17476348.2020.1718495. Epub 2020 Jan 23.
7
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.生物制剂（贝那利珠单抗、度普利尤单抗、美泊利单抗、奥马珠单抗和瑞利珠单抗）治疗重度嗜酸性粒细胞性哮喘的疗效和安全性。EAACI指南的系统评价——关于生物制剂在重度哮喘中应用的建议
Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24.
8
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.美泊利单抗、贝那利珠单抗和泼尼松龙治疗嗜酸性粒细胞性哮喘的血液嗜酸性粒细胞清除情况
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1314-1316. doi: 10.1164/rccm.202003-0729LE.
9
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.倍利珠单抗治疗重度哮喘：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2018 Mar 21;12:619-628. doi: 10.2147/DDDT.S155307. eCollection 2018.
10
The clinical profile of benralizumab in the management of severe eosinophilic asthma.贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘的临床概况。
Ther Adv Respir Dis. 2016 Dec;10(6):534-548. doi: 10.1177/1753465816667659. Epub 2016 Sep 9.

引用本文的文献

1
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma.美泊利珠单抗改变城市哮喘儿童鼻气道2型和上皮炎症的基因调控网络。
Nat Commun. 2025 Sep 2;16(1):8191. doi: 10.1038/s41467-025-63629-2.
2
Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review.以生物制剂试验为重点的已确立和新兴哮喘生物标志物：叙述性综述
J Pers Med. 2025 Aug 13;15(8):370. doi: 10.3390/jpm15080370.
3
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.
嗜酸性粒细胞驱动型与嗜酸性粒细胞相关型重度哮喘：靶向治疗的实际意义
Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729.
4
Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action.重度哮喘中跨越T2炎症谱的哮喘生物制剂：生物标志物与作用机制
J Asthma Allergy. 2025 Jan 14;18:33-57. doi: 10.2147/JAA.S496630. eCollection 2025.
5
Type 2 inflammation in COPD: is it just asthma?慢性阻塞性肺疾病中的2型炎症：它只是哮喘吗？
Breathe (Sheff). 2024 Nov 12;20(3):230229. doi: 10.1183/20734735.0229-2023. eCollection 2024 Oct.
6
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.贝那鲁肽在既往生物制剂治疗和关键临床亚组中的严重嗜酸性粒细胞性哮喘：真实世界 XALOC-1 项目。
Eur Respir J. 2024 Jul 11;64(1). doi: 10.1183/13993003.01521-2023. Print 2024 Jul.
7
Exploring the Role of Nitric Oxide in Lower Airway Diseases: Insights and Real-world Application.探索一氧化氮在下呼吸道疾病中的作用：见解与实际应用
Curr Med Chem. 2024;31(37):6013-6017. doi: 10.2174/0109298673289734231228105444.
8
Severe Asthma and Biological Therapies: Now and the Future.重度哮喘与生物疗法：现状与未来
J Clin Med. 2023 Sep 8;12(18):5846. doi: 10.3390/jcm12185846.
9
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.生物制剂治疗过敏性重症哮喘患者的疗效，总体及基于血嗜酸性粒细胞计数：文献综述。
Adv Ther. 2023 Nov;40(11):4721-4740. doi: 10.1007/s12325-023-02647-2. Epub 2023 Sep 12.
10
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.儿童和青少年重症哮喘管理的新进展：聚焦度普利尤单抗和特泽鲁单抗。
Paediatr Drugs. 2023 Nov;25(6):677-693. doi: 10.1007/s40272-023-00589-4. Epub 2023 Sep 2.